All Hamamatsu University articles
-
NewsGenetically engineered Bifidobacterium shows potential for oral delivery of cancer vaccines
A novel oral vaccine platform using genetically engineered Bifidobacterium could enhance anti-tumor immunity. In an exploratory phase I clinical study, the vaccine was well tolerated and generated immunologic and clinical findings that warrant further investigation.